The secreted aspartic proteinases as a new target in the therapy of candidiasis

被引：24

作者：

Bein, M ^{[1
]}

Schaller, M ^{[1
]}

Korting, HC ^{[1
]}

机构：

[1] Univ Munich, Dept Dermatol & Allergol, Dept Dermatol, D-80337 Munich, Germany

来源：

CURRENT DRUG TARGETS | 2002年 / 3卷 / 05期

关键词：

D O I：

10.2174/1389450023347542

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Secreted aspartic proteinases (Saps) are important virulence factors in different types of candidiasis caused by Candida albicans (C. albicans). The various isoenzymes are expected to fulfil different tasks during mucosal or disseminated infections. It could be shown that the, introduction of the proteinase inhibitors like saquinavir and indinavir in the therapy of human immunodeficiency virus (HIV) infected patients has an effect on Sap activity in vitro as well as in vivo. Therefore, drugs like the HIV proteinase inhibitors could play an essential role in the treatment of candidiasis in the future, especially if further adapted to this target.

引用

页码：351 / 357

页数：7

共 39 条

[1]

AbadZapatero C, 1996, PROTEIN SCI, V5, P640

[2] Trends in antifungal susceptibility among Candida sp urinary isolates from 1994 and 1998 [J].

Baran, J ;

Klauber, E ;

Barczak, J ;

Riederer, K ;

Khatib, R .

JOURNAL OF CLINICAL MICROBIOLOGY, 2000, 38 (02) :870-871

[3] The expression of the secreted aspartyl proteinases Sap4 to Sap6 from Candida albicans in murine macrophages [J].

Borg-von Zepelin, M ;

Beggah, S ;

Boggian, K ;

Sanglard, D ;

Monod, M .

MOLECULAR MICROBIOLOGY, 1998, 28 (03) :543-554

[4] HIV-protease inhibitors reduce cell adherence of Candida albicans strains by inhibition of yeast secreted aspartic proteases [J].

Borg-von Zepelin, M ;

Meyer, I ;

Thomssen, R ;

Würzner, R ;

Sanglard, D ;

Telenti, A ;

Monod, M .

JOURNAL OF INVESTIGATIVE DERMATOLOGY, 1999, 113 (05) :747-751

[5] APPLICATION OF A FLUOROGENIC SUBSTRATE IN THE ASSAY OF PROTEOLYTIC ACTIVITY AND IN THE DISCOVERY OF A POTENT INHIBITOR OF CANDIDA-ALBICANS ASPARTIC PROTEINASE [J].

CAPOBIANCO, JO ;

LERNER, CG ;

GOLDMAN, RC .

ANALYTICAL BIOCHEMISTRY, 1992, 204 (01) :96-102

[6] Clinically significant azole cross-resistance in Candida isolates from HIV-positive patients with oral candidosis [J].

Cartledge, JD ;

Midgley, J ;

Gazzard, BG .

AIDS, 1997, 11 (15) :1839-1844

[7] In vitro and in vivo anticandidal activity of human immunodeficiency virus protease inhibitors [J].

Cassone, A ;

De Bernardis, F ;

Torosantucci, A ;

Tacconelli, E ;

Tumbarello, M ;

Cauda, R .

JOURNAL OF INFECTIOUS DISEASES, 1999, 180 (02) :448-453

[8] Role of protease inhibitors in preventing recurrent oral candidosis in patients with HIV-infection: A prospective case-control study [J].

Cauda, R ;

Tacconelli, E ;

Tumbarello, M ;

Morace, G ;

De Bernardis, F ;

Torosantucci, A ;

Cassone, A .

JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 1999, 21 (01) :20-25

[9] Evidence for degradation of gastrointestinal mucin by Candida albicans secretory aspartyl proteinase [J].

Colina, AR ;

Aumont, F ;

Deslauriers, N ;

Belhumeur, P ;

deRepentigny, L .

INFECTION AND IMMUNITY, 1996, 64 (11) :4514-4519

[10] THE CRYSTAL-STRUCTURE OF A MAJOR SECRETED ASPARTIC PROTEINASE FROM CANDIDA-ALBICANS IN COMPLEXES WITH 2 INHIBITORS [J].

CUTFIELD, SM ;

DODSON, EJ ;

ANDERSON, BF ;

MOODY, PCE ;

MARSHALL, CJ ;

SULLIVAN, PA ;

CUTFIELD, JF .

STRUCTURE, 1995, 3 (11) :1261-1271

← 1 2 3 4 →